Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18640593 | 0.75 | KDM4E (0.41) | KDM4EALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL18198244 | 0.74 | CCR1 (0.39) | KDM4EALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL29760903 | 0.72 | KDM4E (0.42) | KDM4EALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL8029116 | 0.72 | KDM4E (0.42) | KDM4EALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL18149543 | 0.72 | KDM4E (0.38) | KDM4EALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL18150511 | 0.71 | KDM4E (0.41) | KDM4EALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL17433348 | 0.70 | KDM4E (0.43) | KDM4EALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL26310497 | 0.68 | RAB9A (0.37) | KDM4EALDH1A1HPGDUSP2HSD17B10 | |
| SCHEMBL23269421 | 0.68 | CCR1 (0.33) | KDM4EALDH1A1CCR1RAB9ACCR5 | |
| SCHEMBL3067223 | 0.68 | KDM4E (0.42) | KDM4EALDH1A1HPGDUSP2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | KDM4E 4111/4885ALDH1A1 1402/4885HPGD 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.